Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00232154 | A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To | PHASE2 | COMPLETED | 72 | — | — | Nov 1, 2005 | Jun 1, 2006 | Apr 21, 2011 | 18 | United States |
| Name | Type | Description |
|---|---|---|
| Zithromax™ (azithromycin) 500mg tablets | DRUG | - |
| Endoscopic Sinus Surgery | PROCEDURE | - |
| Blood sampling for hematology | PROCEDURE | - |
| Blood sampling for plasma chemistry profile | PROCEDURE | - |
| Serum pregnancy test (for women of child-bearing potential) | PROCEDURE | - |
Inclusion Criteria: * Subjects considered by the Principal Investigator as an appropriate candidate for endoscopic sinus surgery, e.g., for the removal of the thickened and diseased mucosal tissue that blocks the ostiomeatal complex (OMC). Exclusion Criteria: * Known or suspected hypersensitivity...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Itepekimab, Mometasone furoate, Dupilumab |
| Optinose US Inc. | OPTN | 1 | PHASE3 | OPN-375 |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | — | DUPIXENT |